Compare Quantumscape Corp (QS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantumscape Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Quantumscape Corp trades at $5.25 (market cap $3.44B), while State Street SPDR S&P Biotech ETF trades at $159.93. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| QS | XBI | |
|---|---|---|
Market Cap | $3.44B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $18.44 | $169.55 |
52-Week Low | $4.89 | $93.43 |
Enterprise Value | $2.65B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QuantumScape trades at $5.59, up 2.01% today but near 52-week lows, with a bearish technical signal from moving averages. The company is pre-revenue, reporting a net loss of $435.05M in 2025, negative ROE of -39.08%, and cash burn from operations. Recent news highlights insider sales and delayed commercialization timelines, with solid-state battery production not expected until 2029.
Outlook remains speculative with high execution risk; analyst consensus is cautious (0% buy, 73% hold, 27% sell). Investment hinges on successful battery commercialization by 2029, but competition and funding needs pose significant threats to shareholder value amid persistent losses.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
